Risk of Persistent Opioid Use a Concern for Youth After Surgery

Share this content:
Risk of Persistent Opioid Use a Concern for Youth After Surgery
Risk of Persistent Opioid Use a Concern for Youth After Surgery

MONDAY, Dec. 4, 2017 (HealthDay News) -- Adolescents and young adults are at risk for persistent opioid use after surgery, and this represents an important pathway to consider in the epidemic of prescription opioid misuse, according to a study published online Dec. 4 in Pediatrics.

Calista M. Harbaugh, M.D., from the University of Michigan in Ann Arbor, and colleagues performed a retrospective cohort study involving opioid-naive patients aged 13 to 21 years who underwent one of 13 operations. As a comparison, a random sample of 3 percent of nonsurgical patients who matched eligibility criteria was included.

The researchers found that 60.5 percent of eligible patients filled a postoperative opioid prescription. In 4.8 percent of patients there was persistent opioid use (2.7 to 15.2 percent across procedures), compared with 0.1 percent in the nonsurgical group. The highest risk of persistent opioid use was seen in association with cholecystectomy and colectomy (adjusted odds ratios, 1.13 and 2.33, respectively). Older age, female sex, previous substance use disorder, chronic pain, and preoperative opioid fill were independent risk factors.

"Persistent opioid use after surgery is a concern among adolescents and young adults and may represent an important pathway to prescription opioid misuse," the authors write. "Identifying safe, evidence-based practices for pain management is a top priority, particularly among at-risk patients."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »